Hepatitis C Main Section
FDA-approved Monotherapies
FDA-approved Combination Therapies
Intron A
Roferon

Infergen
Pegasys
PEG-Intron
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Link to Hepatitis C Main Section

HCV - ALT / AST and ALT / AST Ratio (AAR)

New Upper Limit Defined for Normal ALT in Adolescent Males - 2/26/08

Silymarin (Milk Thistle) Does Not Affect Hepatitis C Virus Activity or ALT Levels in HCV Patients, but Users Report Fewer Symptoms and Better Quality of Life than Non Users - 2/05/08

Elevated ALT and AST Predict Higher Mortality in General Population 11/14/06

Pancaspase Inhibitor PF-03491390 Reduces ALT and AST Levels in Hepatitis C Patients   11/10/06

Detection of HCV RNA in the Livers of Patients with "Undetectable" Viral Load and Normal ALT - 7/18/06

African Americans More Likely to Have Normal ALT, Less Fibrosis - 6/13/06

Implications of Normal ALT and Initially Mild Liver Disease - 6/13/06

Natural Course of Hepatitis C Virus-infected Patients with Normal ALT and the Effect of Interferon Therapy on Hepatocellular Carcinoma in Those with Elevated ALT- 10/21/05